Skip to content

Clinical Trials Of Icosapent Ethyl Claiming To Reduce The Cardiovascular Events

  • by

Being the leading cause of death among people around the world, CVDs i.e. cardiovascular diseases are tolling humans with its adverse effects. Every year the death count is increased and so as the number of potential patients. Blaming it to the unhealthy lifestyles, eating habits or lack of exercise, cardiovascular diseases are quite common in children and adults. In this episode, Earthy Perks gave detailed information about a trial named REDUCE-IT. It claims for reducing cardiovascular events. Now, how much it is successful in its claims, go and watch the episode. And if you wish to read the bundle of information, you can visit us at

We are talking about cvd cardiovascular diseases being a number-one cause of death globally more people die annually from cvd s than from any other cause understanding the importance and lethality of cvd x’ earthy perks takes this initiative responsibly to talk about cardiovascular events in this episode an estimated seventeen point nine million people died from cvd s

In 2016 representing thirty-one percent of all global deaths of these deaths eighty-five percent are due to heart attack and stroke over three-quarters of cvd deaths take place in low and middle-income countries all these statistics make it clear that there should be something which can at least reduce cardiovascular events to proceed but this something scientists

Are here with a new approach or in other words a drug that claims to reduce the cv ds they call it as ipe a cosa pentothal the trial was way successful the goal of the trial was to assess the safety and benefit of ikos apin ethyl compared with placebo in reducing cardiovascular events among patients with high triglycerides researchers turn these trials as reduce

It according to this the use of ipe to grams twice daily was superior to placebo and reducing tgs cv events and cv death it was also significant for those at high risk for developing cvd and who were already on statin therapy with relatively well controlled ldl levels it took approximately four point nine years to follow up on the results in nineteen thousand two

Hundred and twelve patients all in their main ages of 64 years there was a total of 28 percent of female patients the inclusion criteria for patients to be a part of this trial was to be at the age of 45 years with established cv disease or the age of 50 years with diabetes their fasting tg was from 150 to 499 milligrams two deciliters and low-density lipoprotein

Cholesterol levels from 41 and 100 milligrams two deciliters other criteria were severe heart failure active severe liver disease glycated hemoglobin levels planned coronary intervention or surgery history of acute or chronic pancreatitis and known hypersensitivity to finish shellfish or ingredients of ipe or placebo the principal findings for cv outcome of cv

Death non-fatal myocardial infarction stroke coronary revascularization or unstable angina for ipe versus placebo it was seventeen point two percent versus twenty-two percent other findings included the assumed cost of ipe to be four dollars and sixteen cents per day it concluded that ipe was cost saving in the majority of simulations overall ip he appeared to be

The cost dominant compared with the placebo benefits noted will be on those that could be explained by the degree of tg or other biomarker changes such as ldl cholesterol hdl in hsc rp though results of this trial indicate that the use of ip e to grams twice daily was superior to placebo reducing tgs cv events and cv death among patients rates of revascularization

And mi were lower while atrial fibrillation or flutter and bleeding were higher with ip e reduce it came as a ray of hope against the backdrop of multiple unsuccessful cardiovascular outcome studies of early generation drug therapies including multiple recent failed cardiovascular studies of omega-3 mixture products that contain the omega-3 acid dha reduce at top

Line results stand alone as positive and confirm the hypothesis that pure ep ava sepa at four grams per day can provide additional cardiovascular risk reduction these fanciful capsules are a single molecule prescription products consisting omega-3 acid commonly known as epa in ethyl ester form vas sepa is not fishery but it is derived from fish through a stringent

And complex fda regulated manufacturing process out of all pharmaceutical enterprises a marine corporation is a rapidly growing innovated pharmaceutical company focused on developing therapeutics to improve cardiovascular health vasa is a moran’s first fda-approved drug and is available by prescription in the united states lebanon and the united arab emirates to

Reduce triglyceride levels and adult patients with severe hypertriglyceridemia if not eliminating it from the root at least this drug is successful in reducing the effects and the wrist this is earthy perks signing off with the promise to bring the latest in most interesting episodes and contents till then stay tuned and keep watching

Transcribed from video
Clinical Trials Of Icosapent Ethyl Claiming To Reduce The Cardiovascular Events By Earthy Perks